AMGN241115C400000
- 0.01
- -0.04-80.00%
Amgen Newsroom
Amgen To Go Ex-Dividend On November 18th, 2024 With 2.25 USD Dividend Per Share
Market Falls Thursday, Powell Said Fed Will Take Things Slow | Wall Street Today
Wolfe Research Maintains Amgen(AMGN.US) With Hold Rating
Express News | Amgen Presents New Data Across Rare Inflammatory Diseases at Acr 2024
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
5 Healthcare Stocks to Buy in a Beaten-Up Sector -- Barrons.com
Dow's 111-Point Drop Led By Losses For Salesforce, Cisco Stocks
Amgen's Options Frenzy: What You Need to Know
Thursday Market Chills From Election Celebration | Live Stock
Evercore Maintains Amgen(AMGN.US) With Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $383
Today's Analyst Rating | NVIDIA Price Target Raised to $175 by Oppenheimer, Amazon Price Target Raised to $250 by Needham
Amgen Analyst Ratings
Express News | Amgen Inc : Citigroup Initiates Coverage With Neutral Rating; Price Target $335
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
Bitcoin Gets Closer to $100k Than Ever | Wall Street Today
Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Express News | Amgen Exec Says Some Supplemental Maritide Data Published Were Not Subject to Our Standard Institutional Review,